BIO-TECHNE Corp (NASDAQ:TECH)’s share price reached a new 52-week high on Wednesday . The stock traded as high as $149.06 and last traded at $149.06, with a volume of 22400 shares trading hands. The stock had previously closed at $148.68.
Several research firms have weighed in on TECH. BidaskClub upgraded BIO-TECHNE from a “hold” rating to a “buy” rating in a report on Wednesday, January 10th. Zacks Investment Research raised BIO-TECHNE from a “hold” rating to a “buy” rating and set a $148.00 price target for the company in a research note on Saturday, February 10th. Robert W. Baird raised their price target on BIO-TECHNE from $154.00 to $157.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 7th. Craig Hallum reissued a “buy” rating and set a $160.00 price target (up from $140.00) on shares of BIO-TECHNE in a research note on Wednesday, February 7th. Finally, Deutsche Bank set a $163.00 price target on BIO-TECHNE and gave the stock a “buy” rating in a research note on Thursday, March 1st. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. BIO-TECHNE has a consensus rating of “Buy” and an average price target of $148.60.
The company has a debt-to-equity ratio of 0.36, a quick ratio of 2.49 and a current ratio of 3.10. The company has a market capitalization of $5,545.40, a PE ratio of 48.86, a price-to-earnings-growth ratio of 2.84 and a beta of 0.75.
The business also recently declared a quarterly dividend, which was paid on Friday, March 2nd. Stockholders of record on Friday, February 16th were issued a $0.32 dividend. The ex-dividend date of this dividend was Thursday, February 15th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.86%. BIO-TECHNE’s dividend payout ratio is presently 41.97%.
In other news, Director Charles A. Dinarello sold 5,000 shares of BIO-TECHNE stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $136.06, for a total value of $680,300.00. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 3.40% of the company’s stock.
A number of hedge funds have recently made changes to their positions in the stock. Amalgamated Bank grew its stake in BIO-TECHNE by 5.4% during the 4th quarter. Amalgamated Bank now owns 7,772 shares of the biotechnology company’s stock worth $1,007,000 after buying an additional 399 shares during the last quarter. Meadow Creek Investment Management LLC lifted its position in BIO-TECHNE by 14.3% during the 4th quarter. Meadow Creek Investment Management LLC now owns 3,520 shares of the biotechnology company’s stock worth $456,000 after acquiring an additional 440 shares during the period. Jane Street Group LLC lifted its position in BIO-TECHNE by 17.5% during the 4th quarter. Jane Street Group LLC now owns 3,016 shares of the biotechnology company’s stock worth $391,000 after acquiring an additional 449 shares during the period. Oppenheimer Asset Management Inc. lifted its position in BIO-TECHNE by 3.9% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 12,180 shares of the biotechnology company’s stock worth $1,473,000 after acquiring an additional 452 shares during the period. Finally, Pacer Advisors Inc. lifted its position in BIO-TECHNE by 11.5% during the 3rd quarter. Pacer Advisors Inc. now owns 4,846 shares of the biotechnology company’s stock worth $586,000 after acquiring an additional 500 shares during the period. Hedge funds and other institutional investors own 97.12% of the company’s stock.
BIO-TECHNE Company Profile
Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.
Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with MarketBeat.com's FREE daily email newsletter.